513 Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): A Phase Ib study

Giaccone, Giuseppe; Camidge, D. Ross; Liu, S.V.; Powderly, John D.; Hodi, F. Stephen; Gettinger, Scott; Heist, Rebecca S.; Liu, B.; Wallin, JE; Funke, Roel; Waterkamp, Daniel; Ready, Neal

doi:10.1016/s0959-8049(16)30314-8

Cited by 14 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a preliminary analysis of a Phase IB trial of patients with various solid tumors, a cohort of 16 efficacy-evaluable patients with advanced NSCLC treated with the combination of atezolizumab (15 mg/kg q3w) plus nab -paclitaxel (100 mg/m 2 weekly) plus carboplatin achieved an ORR of 56% and a complete response rate of 25% 83,84. Two other trial arms of atezolizumab plus either paclitaxel/carboplatin (efficacy evaluable, n=8) or pemetrexed/carboplatin (efficacy evaluable, n=17) also demonstrated favorable ORRs of 50% and 76%, respectively, but no patients receiving the paclitaxel- or pemetrexed-containing regimens have achieved a complete response to date.…”

Section: Chemotherapy In Combination With Checkpoint Inhibitorsmentioning

confidence: 99%

<em>nab</em>-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors

Soliman

2016

OTT

View full text Add to dashboard Cite

Tumors recognized by the host immune system are associated with better survival. However, the immune system is often suppressed in patients with established tumor burden. Stimulating the immune system to detect and kill tumor cells has been a challenge in cancer therapy for some time. Recently, novel cancer immunotherapies, such as immune checkpoint inhibitors, monoclonal antibodies, and vaccine therapies, have emerged as promising therapeutic approaches for many solid tumors. However, for some tumors, immunotherapy alone has not provided significant benefits, and some may even be fully resistant to immunotherapy. It has been suggested that the immune system may require “priming” before an immunotherapy can elicit an immune response. Although chemotherapies are believed to be immunosuppressive, when given at the right dose and sequence these agents may provide this “priming” effect for the immune system. In addition to direct cytotoxic killing of tumor cells, standard chemotherapeutic agents can elicit immunogenicity through various mechanisms. This review highlights the general immunomodulatory properties of chemotherapy agents. It also provides a rationale for combined therapy with nab-paclitaxel and immune checkpoint inhibitors. Recent clinical trial data with these combination regimens in solid tumors are presented, along with a summary of ongoing trials.

show abstract

Section: Chemotherapy In Combination With Checkpoint Inhibitorsmentioning

confidence: 99%

<em>nab</em>-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors

Soliman

2016

OTT

View full text Add to dashboard Cite

show abstract

“…82 Up to the data cutoff in February 2015, 58 NSCLC patients in total were assigned to arms C, D, and E to receive different chemotherapy combinations, along with atezolizumab at the same dose of 15 mg/kg (q3w). High response rate (64%) was achieved with no expected toxicity.…”

Section: Combined With Chemotherapymentioning

confidence: 99%

Management of Italian Patients With Advanced Non–Small-Cell Lung Cancer After Second-Line Treatment: Results of the Longitudinal Phase of the LIFE Observational Study

Marinis

Ardizzoni

Fontanini

et al. 2014

Clinical Lung Cancer

View full text Add to dashboard Cite

“…Patient demographics were provided initially for the safety evaluable population but not in the efficacy evaluable population ( n = 76) ( 10 , 11 ). Among the patients that were evaluated, the confirmed ORR was the highest in arm D, although the medians and confidence intervals were not provided.…”

Section: Resultsmentioning

confidence: 99%

Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects

Ryu

Ward

2018

Front. Oncol.

View full text Add to dashboard Cite

Purpose: Atezolizumab is a programmed death ligand 1 (PDL-1) blocking antibody that was approved for metastatic non-small cell lung cancer (NSCLC) in patients with disease progression. Various studies have been initiated to explore the effectiveness of atezolizumab among different patient cohorts and disease statuses, including as first-line therapy. The purpose of this paper is to identify and summarize the trials that use atezolizumab as a first-line agent in chemotherapy-naïve patients with NSCLC.Methods: A database search was performed on Pubmed, Embase, and Wiley Cochrane Library—Central Register of Controlled Trials to identify clinical trials using atezolizumab as first-line therapy in NSCLC. Additionally, ClinicalTrials.gov and the International Clinical Trials Registry Platform (ICTRP) were searched to identify relevant clinical trials. Conference abstracts from the American Society of Clinical Oncology, the European Society for Medical Oncology, and the American Association for Cancer Research were hand-searched. Any trial in which atezolizumab was used as first-line therapy in chemotherapy-naive patients with NSCLC was included.Results: Fifteen studies were ultimately included, all of which are current and ongoing. Of the 15 studies, 5 have reported results. When given in the first-line setting, atezolizumab had higher rates of objective response, progression-free survival, and overall survival, compared to the second and third-line settings. Among the 15 studies, atezolizumab is used as monotherapy (n = 5), in combination with chemotherapy (n = 6), in combination with targeted therapy such as bevacizumab (n = 1), as neoadjuvant/adjuvant therapy (n = 3), in combination with stereotactic body radiation therapy (n = 1), and in combination with or following chemoradiation (n = 1).Conclusion: Available evidence shows promising safety and efficacy with the use of atezolizumab as first-line therapy in NSCLC. Atezolizumab is currently being studied in a variety of treatment settings. If clinical benefits are shown, atezolizumab may deem to be a useful first-line agent in NSCLC.

show abstract

513 Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): A Phase Ib study

Cited by 14 publications

References 0 publications

<em>nab</em>-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors

<em>nab</em>-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors

Management of Italian Patients With Advanced Non–Small-Cell Lung Cancer After Second-Line Treatment: Results of the Longitudinal Phase of the LIFE Observational Study

Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects

Contact Info

Product

Resources

About